Nephrology Doctors in Hazard, KY Accepting Medicare

3 Nephrology doctors found. Showing 1 - 3

Kurt Sowers, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr Ste 1p, Hazard, KY 41701 Phone: 606-487-7991    Fax: 606-439-6685

Dr. Jyotin Chandarana, M.D. Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 755 Morton Blvd, Hazard, KY 41701 Phone: 606-436-5769    Fax: 606-436-0601

Dr. Kassaw A Joseph, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600    Fax: 606-439-6953

News Archive

Targeting TAAR5 can provide a new treatment opportunity for neurodegenerative disorders

St Petersburg University researchers, led by Professor Raul R. Gainetdinov, Director of the Institute of Translational Biomedicine and Academic Supervisor of the St Petersburg University Hospital, have found a new role for recently discovered neurotransmitter system that uses the trace amine-associated receptor 5 (TAAR5) for neurotransmission.

Cardiopulmonary exercise testing may predict post-liver transplantation survival

Researchers from the U.K. determined that preoperative cardiopulmonary exercise testing (CPET) is a specific predictor of 90-day survival following liver transplantation. Study results available in the February issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases, shows that the CPET measurement—the anaerobic threshold or fitness level—significantly predicts mortality in patients post-transplantation.

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.

Article outlines new approach for reviewing potential downsides of screening recommendation

Screening to detect medical conditions has become standard practice for many diseases, but insufficient attention has been paid to the potential for harm, according to research conducted at the University of North Carolina.

Read more Medical News

› Verified 3 days ago